Tag: Tissue factor-targeted treatment

Home / Tissue factor-targeted treatment

Categories

Tisotumab vedotin-tftv is approved by the FDA for recurrent or metastatic cervical cancer

April 2024: Tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) has received formal approval from the Food and Drug Administration for the treatment of recurrent or metastatic cer...
tissue-factor-targeted-treatment

We Are Online! Chat With Us!
Scan the code